Finerenone and Hypotension Risk in Heart Failure: Evidence from the FINEARTS-HF Trial

MedXY Editorial Team•Dec 26, 2025•Cardiology

Finerenone significantly increases the incidence of post-baseline systolic blood pressure (SBP) <100 mm Hg and investigator-reported hypotension in patients with HFmrEF and HFpEF.
The primary clinical benefits of finerenone (reduction in HF events and CV death) remain robust in patients who do not experience hypotension, though the effect may attenuate following a hypotensive event.
Key predictors for hypotension include advanced age, lower baseline SBP, higher NT-proBNP levels, and a history of smoking.
Clinicians are advised to monitor blood pressure closely rather than automatically discontinuing finerenone upon the observation of low SBP.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Finerenone significantly increases the incidence of post-baseline systolic blood pressure (SBP) <100 mm Hg and investigator-reported hypotension in patients with HFmrEF and HFpEF.
The primary clinical benefits of finerenone (reduction in HF events and CV death) remain robust in patients who do not experience hypotension, though the effect may attenuate following a hypotensive event.
Key predictors for hypotension include advanced age, lower baseline SBP, higher NT-proBNP levels, and a history of smoking.
Clinicians are advised to monitor blood pressure closely rather than automatically discontinuing finerenone upon the observation of low SBP.